BioTuesdays

Tag - CLNN

Clene Logo

Clene shares down 29% after Phase 2 ALS trial fails

Shares of Clene (NASDAQ:CLNN) tumbled 29% after its lead drug candidate, CNM-Au8, an investigational gold nanocrystal suspension, missed key endpoints in a platform study in amyotrophic lateral sclerosis (ALS), a...

Clene Logo

HCW starts Clene at buy; PT $16

H.C.Wainwright initiated coverage of Clene (NASDAQ:CLNN) with a “buy” rating and price target of $16. The stock closed at $4.50 on July 15. Clene is focused on the development of novel clean-surfaced nanotechnologies...

Clene-Nanomedicine

Maxim starts Clene at buy; PT $18

Maxim Group launched coverage of Clene (NASDAQ:CLNN) with a “buy” rating and $18 price target. The stock closed at $8.95 on May 19. Clene is a clinical-stage company developing CNM-Au8, an oral, clean-surfaced faceted...

Clene-Nanomedicine

Cantor starts Clene at OW; PT $22

Cantor Fitzgerald launched coverage of Clene (NASDAQ:CLNN) with an “overweight” rating and 12-month price target of $22. The stock closed at $9 on April 30. Clene is a neuro-innovator that is developing drugs to enhance...